

Virtual General Assembly

15 & 16 October 2020

Thursday, 15th October 2020

15:00 - 15:30

Welcome & Update

J Hernández
and F Calado

15:30 - 17:30

ALL & Ped AML & APL CLL MDS MM NHL

Parallel
discussions
per disease
project

17:30 - 18:30

Delphi Surveys

K Lang, T
Berezcky, R
Schulze-Rath

Friday, 16th October 2020

15:00 - 16:00

Sustainability

M Müller

16:00 - 16:20

Future perspective

G Sanz and
D Nesheiwat

16:20 - 16:40

HARMONY PLUS

J Hernández
and F Calado

16:40 - 18:00

Upcoming projects in HARMONY and HARMONY PLUS – L Bullinger and F Ali

- MPN & COVID-19 (Barbui)
- Epidemiology of COVID-19 in patients with HMs (Pagano & Cornely)
- Harmony for Validation of the findings of the Machine Learning Analysis of OPTUM in polycythaemia vera patients (Santiago Redondo)
- MRD AML (Ossenkoppele)
- CML in HARMONY Plus (Hochhaus)

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

#bigdataforbloodcancer: Enabling Better and Faster Treatment for Patients with Hematologic Malignancies.
www.harmony-alliance.eu | [@harmonyNetEU](https://twitter.com/harmonyNetEU)